Literature DB >> 19375222

Autoantibodies in complex regional pain syndrome bind to a differentiation-dependent neuronal surface autoantigen.

Danielle Kohr1, Marlene Tschernatsch, Katrin Schmitz, Pratibha Singh, Manfred Kaps, Karl-Herbert Schäfer, Martin Diener, Janina Mathies, Oliver Matz, Wolfgang Kummer, Christian Maihöfner, Thorsten Fritz, Frank Birklein, Franz Blaes.   

Abstract

Complex regional pain syndrome, which is characterised by pain and trophic disturbances, develops frequently after peripheral limb trauma. There is an increasing evidence of an involvement of the immune system in CRPS, and recently we showed that CRPS patients have autoantibodies against nervous system structures. Therefore we tested the sera of CRPS patients, neuropathy patients and healthy volunteers for surface-binding autoantibodies to primary cultures of autonomic neurons and differentiated neuroblastoma cell lines using flow cytometry. Thirteen of 30 CRPS patients, but none of 30 healthy controls and only one of the 20 neuropathy sera had specific surface binding to autonomic neurons (p<0.001). The majority of the sera reacted with both sympathetic and myenteric plexus neurons. Interestingly, 6/30 CRPS sera showed binding to undifferentiated SH-SY5Y neuroblastoma cells. However, differentiation of SH-SY5Y into a cholinergic phenotype induced a surface antigen, which is recognised by 60% of CRPS sera (18/30), but not by controls (p<0.001). Our data show that about 30-40% of CRPS patients have surface-binding autoantibodies against an inducible autonomic nervous system autoantigen. These data support an autoimmune hypothesis in CRPS patients. Further studies must elucidate origin and function of these autoantibodies in CRPS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19375222     DOI: 10.1016/j.pain.2009.03.009

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  32 in total

1.  Current Concepts in Adult CRPS.

Authors:  Andreas Goebel
Journal:  Rev Pain       Date:  2011-06

Review 2.  Clinical features and pathophysiology of complex regional pain syndrome.

Authors:  Johan Marinus; G Lorimer Moseley; Frank Birklein; Ralf Baron; Christian Maihöfner; Wade S Kingery; Jacobus J van Hilten
Journal:  Lancet Neurol       Date:  2011-07       Impact factor: 44.182

3.  Endoneurial pathology of the needlestick-nerve-injury model of Complex Regional Pain Syndrome, including rats with and without pain behaviors.

Authors:  M M Klein; J W Lee; S M Siegel; H M Downs; A L Oaklander
Journal:  Eur J Pain       Date:  2012-01       Impact factor: 3.931

Review 4.  [Complex regional pain syndrome: A current review].

Authors:  C Maihöfner
Journal:  Schmerz       Date:  2014-06       Impact factor: 1.107

5.  Autoantibodies against P29ING4 are associated with complex regional pain syndrome.

Authors:  N T Baerlecken; R Gaulke; N Pursche; T Witte; M Karst; M Bernateck
Journal:  Immunol Res       Date:  2019-12       Impact factor: 2.829

Review 6.  Immunoglobulin responsive chronic pain.

Authors:  Andreas Goebel
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

Review 7.  Autonomic dysfunction and HPV immunization: an overview.

Authors:  Svetlana Blitshteyn; Louise Brinth; Jeanne E Hendrickson; Manuel Martinez-Lavin
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

8.  Identification of KRT16 as a target of an autoantibody response in complex regional pain syndrome.

Authors:  Maral Tajerian; Victor Hung; Hamda Khan; Lauren J Lahey; Yuan Sun; Frank Birklein; Heidrun H Krämer; William H Robinson; Wade S Kingery; J David Clark
Journal:  Exp Neurol       Date:  2016-10-20       Impact factor: 5.330

Review 9.  New Concepts in Complex Regional Pain Syndrome.

Authors:  Maral Tajerian; John David Clark
Journal:  Hand Clin       Date:  2016-02       Impact factor: 1.907

10.  Evidence of small-fiber polyneuropathy in unexplained, juvenile-onset, widespread pain syndromes.

Authors:  Anne Louise Oaklander; Max M Klein
Journal:  Pediatrics       Date:  2013-03-11       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.